Shares of Quest PharmaTech Inc. (CVE:QPT – Get Free Report) reached a new 52-week low during mid-day trading on Friday . The company traded as low as C$0.02 and last traded at C$0.02, with a volume of 10798 shares changing hands. The stock had previously closed at C$0.03.
Quest PharmaTech Stock Down 20.0%
The company has a current ratio of 0.40, a quick ratio of 0.52 and a debt-to-equity ratio of 4.35. The firm has a market capitalization of C$3.38 million, a price-to-earnings ratio of 0.67 and a beta of -0.07. The firm has a 50 day moving average price of C$0.03 and a two-hundred day moving average price of C$0.03.
Quest PharmaTech Company Profile
Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class.
Recommended Stories
- Five stocks we like better than Quest PharmaTech
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Quest PharmaTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest PharmaTech and related companies with MarketBeat.com's FREE daily email newsletter.
